A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease

Experimental Neurology

Volumn 205, Issue 1, 2007, Pages 207-213

  Liebetanz, David ^a   Baier, Paul Christian ^a   Paulus, Walter ^a   Meuer, Katrin ^a,b   Bähr, Mathias ^a,b   Weishaupt, Jochen H ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Deutsche Forschungsgemeinschaft   (Germany)

Author keywords

Motor learning; Mouse behaviour; Mouse phenotype; MPTP; Neurodegeneration; Parkinson's disease; Wheel running

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOMATION, COMPUTERS AND DATA PROCESSING; CONTROLLED STUDY; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RUNNING; TREADMILL; VOLUNTARY MOVEMENT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DIAGNOSIS, COMPUTER-ASSISTED; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; DOPAMINE AGENTS; EQUIPMENT DESIGN; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MOTOR SKILLS; PARKINSONIAN DISORDERS; PHYSICAL CONDITIONING, ANIMAL; RECOVERY OF FUNCTION;

EID: 34247205387     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.01.030     Document Type: Article

References (45)

1. Agid Y., Javoy F., and Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat. New Biol. 245 (1973) 150-151
2. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 991 (2003) 120-131
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20 (1973) 415-455
4. Boehm II S.L., Schafer G.L., Phillips T.J., Browman K.E., and Crabbe J.C. Sensitivity to ethanol-induced motor incoordination in 5-HT(1B) receptor null mutant mice is task-dependent: implications for behavioral assessment of genetically altered mice. Behav. Neurosci. 114 (2000) 401-409
5. Chesler E.J., Wilson S.G., Lariviere W.R., Rodriguez-Zas S.L., and Mogil J.S. Influences of laboratory environment on behavior. Nat. Neurosci. 5 (2002) 1101-1102
6. Colotla V.A., Flores E., Oscos A., Meneses A., and Tapia R. Effects of MPTP on locomotor activity in mice. Neurotoxicol. Teratol. 12 (1990) 405-407
7. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
8. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., and Hen R. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14524-14529
9. Dietz G.P., Valbuena P.C., Dietz B., Meuer K., Mueller P., Weishaupt J.H., and Bahr M. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res. 1082 (2006) 61-66
10. Drolet R.E., Behrouz B., Lookingland K.J., and Goudreau J.L. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 25 (2004) 761-769
11. Dupont W.D., and Plummer Jr. W.D. Power and sample size calculations. A review and computer program. Control. Clin. Trials 11 (1990) 116-128
12. Eberhardt O., and Schulz J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol. Lett. 139 (2003) 135-151
13. Eberhardt O., Coelln R.V., Kugler S., Lindenau J., Rathke-Hartlieb S., Gerhardt E., Haid S., Isenmann S., Gravel C., Srinivasan A., Bahr M., Weller M., Dichgans J., and Schulz J.B. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 20 (2000) 9126-9134
14. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., and Chesselet M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 24 (2004) 9434-9440
15. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., and Sudhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3413-3418
16. Fredriksson A., and Archer T. MPTP-induced behavioural and biochemical deficits: a parametric analysis. J. Neural Transm., Parkinson's Dis. Dement. Sect. 7 (1994) 123-132
17. Freyaldenhoven T.E., Ali S.F., and Hart R.W. MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Res. 688 (1995) 161-170
18. Grillner S., and Wallen P. Central pattern generators for locomotion, with special reference to vertebrates. Annu. Rev. Neurosci. 8 (1985) 233-261
19. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
20. Heikkila R.E., and Sonsalla P.K. The MPTP-treated mouse as a model of parkinsonism: how good is it?. Neurochem. Int. 20 (1992) 299S-303S (Suppl.)
21. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 51 (1998) S2-S9
22. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., Rakic P., and Flavell R.A. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 665-670
23. Hwang D.Y., Fleming S.M., Ardayfio P., Moran-Gates T., Kim H., Tarazi F.I., Chesselet M.F., and Kim K.S. 3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J. Neurosci. 25 (2005) 2132-2137
24. Lau Y.S., and Fung Y.K. Pharmacological effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine receptor system. Brain Res. 369 (1986) 311-315
25. Leng A., Mura A., Hengerer B., Feldon J., and Ferger B. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice. Behav. Brain Res. 154 (2004) 375-383
26. Liebetanz D., and Merkler D. Effects of commissural de- and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis. J. Exp. Neurol. (2006)
27. Liebetanz D., Hagemann K., von Lewinski F., Kahler E., and Paulus W. Extensive exercise is not harmful in amyotrophic lateral sclerosis. Eur. J. Neurosci. 20 (2004) 3115-3120
28. Meuer K., Pitzer C., Teismann P., Kruger C., Goricke B., Laage R., Lingor P., Peters K., Schlachetzki J.C., Kobayashi K., Dietz G.P., Weber D., Ferger B., Schabitz W.R., Bach A., Schulz J.B., Bahr M., Schneider A., and Weishaupt J.H. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J. Neurochem. 97 (2006) 675-686
29. Mitra N., Mohanakumar K.P., and Ganguly D.K. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res. Bull. 28 (1992) 355-364
30. Parker Jr. W.D., Boyson S.J., and Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26 (1989) 719-723
31. Pearson, K., 1976. The control of walking. Sci. Am. 235: 2-74, 79-82, 83-76.
32. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., and Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76 (2001) 1265-1274
33. Robertson D.C., Schmidt O., Ninkina N., Jones P.A., Sharkey J., and Buchman V.L. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J. Neurochem. 89 (2004) 1126-1136
34. Rousselet E., Joubert C., Callebert J., Parain K., Tremblay L., Orieux G., Launay J.M., Cohen-Salmon C., and Hirsch E.C. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol. Dis. 14 (2003) 218-228
35. Rozas G., Lopez-Martin E., Guerra M.J., and Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J. Neurosci. Methods 83 (1998) 165-175
36. Rustay N.R., Wahlsten D., and Crabbe J.C. Influence of task parameters on rotarod performance and sensitivity to ethanol in mice. Behav. Brain. Res. 141 (2003) 237-249
37. Schalomon P.M., and Wahlsten D. Wheel running behavior is impaired by both surgical section and genetic absence of the mouse corpus callosum. Brain Res. Bull. 57 (2002) 27-33
38. Schapira A.H., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., Clark J.B., and Marsden C.D. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55 (1990) 2142-2145
39. Sieve A.N., Steelman A.J., Young C.R., Storts R., Welsh T.H., Welsh C.J., and Meagher M.W. Chronic restraint stress during early Theiler's virus infection exacerbates the subsequent demyelinating disease in SJL mice. J. Neuroimmunol. 155 (2004) 103-118
40. Tatton N.A., and Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77 (1997) 1037-1048
41. Tillerson J.L., Caudle W.M., Reveron M.E., and Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp. Neurol. 178 (2002) 80-90
42. Wahlsten D., Rustay N.R., Metten P., and Crabbe J.C. In search of a better mouse test. Trends Neurosci. 26 (2003) 132-136
43. Weihmuller F.B., Bruno J.P., Neff N.H., and Hadjiconstantinou M. Dopamine receptor plasticity following MPTP-induced nigrostriatal lesions in the mouse. Eur. J. Pharmacol. 180 (1990) 369-372
44. West B.D., Shughrue P.J., Vanko A.E., Ransom R.W., and Kinney G.G. Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment. Pharmacol. Biochem. Behav. 84 (2006) 158-161
45. Zigmond M.J., Hastings T.G., and Perez R.G. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity?. Parkinsonism Relat. Disord. 8 (2002) 389-393